Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Shanghai Fosun Pharmaceutical (Group) Co ( (HK:2196) ) has issued an update.
Shanghai Fosun Pharmaceutical announced its unaudited interim results for the first half of 2025, reporting a decrease in revenue to RMB 19.43 billion from RMB 20.38 billion in the same period of 2024. Despite the revenue drop, the company achieved a profit increase, with profit before tax rising to RMB 2.72 billion from RMB 1.93 billion, and profit for the period reaching RMB 2.10 billion, up from RMB 1.55 billion. This improvement was driven by other gains and a reduction in certain expenses, indicating a positive impact on the company’s financial health and potential for future growth.
The most recent analyst rating on (HK:2196) stock is a Hold with a HK$17.20 price target. To see the full list of analyst forecasts on Shanghai Fosun Pharmaceutical (Group) Co stock, see the HK:2196 Stock Forecast page.
More about Shanghai Fosun Pharmaceutical (Group) Co
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is a joint stock limited company based in China, primarily engaged in the pharmaceutical industry. The company focuses on the development, manufacture, and distribution of pharmaceutical products, medical devices, and healthcare services.
Average Trading Volume: 10,877,098
Technical Sentiment Signal: Hold
Current Market Cap: HK$79.26B
Find detailed analytics on 2196 stock on TipRanks’ Stock Analysis page.